• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IRINOTECAN Drug Record

  • Summary
  • Interactions
  • Claims
  • IRINOTECAN chembl:CHEMBL481 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    CAMPTOSAR
    IRINOTECAN
    IRINOTECAN MYLAN
    BIOTECAN
    IRINOTECAN LACTONE
    HSDB 7607
    IRINOPHORE C
    CAMPTOTHECIN-11
    (+)-IRINOTECAN
    chemidplus:97682-44-5
    rxcui:51499
    pubchem.compound:60838
    chembl:CHEMBL481
    drugbank:00762

    Drug Info:

    Year of Approval 1996
    Drug Class antineoplastic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (9 More Sources)

    Publications:

    Freyer G et al., 2011, Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study., Anticancer Res
    Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
    Martinez-Balibrea et al., 2010, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy., Br. J. Cancer
    Kostopoulos et al., 2009, Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy., BMC Cancer
    Yoshikawa et al., 2004, Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells., Int. J. Cancer
    Nakagawa et al., 2006, Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer., Cancer Lett.
    Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.
    Ishikawa et al., 2006, Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells., Curr. Pharm. Des.
    Yang et al., 2005, Novel agents that potentially inhibit irinotecan-induced diarrhea., Curr. Med. Chem.
    Yoshikawa et al., 2004, Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid., J. Exp. Ther. Oncol.
    Chabot, 1997, Clinical pharmacokinetics of irinotecan., Clin Pharmacokinet
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
    de Oliveira Figueiredo P et al., 2014, Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids., Bioorg Med Chem Lett
    Chaniyara R et al., 2013, Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition., J Med Chem
    Hoskins JM et al., 2008, Irinotecan pharmacogenetics: influence of pharmacodynamic genes., Clin Cancer Res
    Takahashi H et al., 2014, Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect., PLoS One
    LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
    Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
    De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.
    Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
    Smakman et al., 2006, KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand., Cancer Res.
    Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
    Gerdes et al., 2013, GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab., Clin. Cancer Res.
    Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
    Maitra et al., 2014, Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan., Oncotarget
    Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
    Hochster et al., 2015, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer., Cancer Chemother. Pharmacol.
    French D et al., 2011, KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing., Clin Chim Acta
    Kinehara et al., 2015, Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer., Lung Cancer
    Li M et al., 2018, ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia., Pharmacogenomics J
    Boisdron-Celle M et al., 2017, A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification., Semin Oncol
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Hsu HC et al., 2016, Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients., Oncotarget
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
    Silkin SV et al., 2016, Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan., J Gastrointest Cancer
    Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
    Hong et al., 2016, Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation., Cancer Discov
    Loupakis et al., 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer., Br. J. Cancer
    Koschmann et al., 2016, ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma., Sci Transl Med
    Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
    Li J et al., 2016, A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients., J Cancer Res Clin Oncol
    Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
    Guemei et al., 2001, Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan., Cancer Chemother. Pharmacol.
    Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Fujita K et al., 2008, Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)., Biol Pharm Bull
    Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
    De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
    Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.
    Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
    Han JY et al., 2013, A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer., Pharmacogenomics J
    Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
    Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.
    Lévesque E et al., 2013, Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens., J Pharmacol Exp Ther
    Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol
    Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
    De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
    Mbatchi LC et al., 2016, Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients., Clin Pharmacokinet
    Al-Ahmadie H et al., 2014 Sep, Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy., Cancer Discov
    Chen S et al., 2015, A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients., Pharmacogenomics J
    Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
    Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
    Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer
    Aguilera et al., 2015, Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer., Oncotarget
    Han JY et al., 2014, A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy., Pharmacogenomics J
    Han JY et al., 2010, Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy., Pharmacogenomics J
  • IRINOTECAN   TOP1MT

    Interaction Score: 4.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CPX-1
    Novel drug target Established target
    Trial Name PEP-02

    PMIDs:
    15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 17016423 17139284


    Sources:
    TdgClinicalTrial

  • IRINOTECAN   SEMA3C

    Interaction Score: 2.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22664479


    Sources:
    PharmGKB

  • IRINOTECAN   RAD50

    Interaction Score: 2.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24934408


    Sources:
    CIViC

  • IRINOTECAN   C8ORF34

    Interaction Score: 2.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22664479


    Sources:
    PharmGKB

  • IRINOTECAN   UBE2I

    Interaction Score: 1.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19859084


    Sources:
    PharmGKB

  • IRINOTECAN   DCBLD1

    Interaction Score: 1.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23478653


    Sources:
    PharmGKB

  • IRINOTECAN   ISG15

    Interaction Score: 1.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • IRINOTECAN   TGFBR2

    Interaction Score: 1.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27160286


    Sources:
    PharmGKB

  • IRINOTECAN   RUNX3

    Interaction Score: 1.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17372756


    Sources:
    NCI

  • IRINOTECAN   ABCG1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • IRINOTECAN   KLC1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • IRINOTECAN   XRCC3

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • IRINOTECAN   CES2

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   UGT1A

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25778466


    Sources:
    PharmGKB

  • IRINOTECAN   RGS5

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25069475


    Sources:
    PharmGKB

  • IRINOTECAN   SHMT1

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22044939


    Sources:
    PharmGKB

  • IRINOTECAN   AREG

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23959273


    Sources:
    PharmGKB

  • IRINOTECAN   DKK1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25788273


    Sources:
    CIViC

  • IRINOTECAN   UGT1A9

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23386248 18221820 16636344 12181437


    Sources:
    PharmGKB

  • IRINOTECAN   ABCC5

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • IRINOTECAN   KCNQ5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25127363


    Sources:
    PharmGKB

  • IRINOTECAN   TOP1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CPX-1
    Novel drug target Established target
    Trial Name irinotecan hydrochloride injection,Camptosar

    PMIDs:
    19775480 15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 25003995 24507920 23360284 18347181


    Sources:
    DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD

  • IRINOTECAN   ATRX

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26936505


    Sources:
    JAX-CKB

  • IRINOTECAN   DPYD

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28395759


    Sources:
    PharmGKB

  • IRINOTECAN   BCHE

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11345644


    Sources:
    NCI PharmGKB

  • IRINOTECAN   SMAD4

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22753594


    Sources:
    JAX-CKB

  • IRINOTECAN   TYMS

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21273624 16456808 20628391


    Sources:
    CIViC PharmGKB

  • IRINOTECAN   E2F1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9766655


    Sources:
    NCI

  • IRINOTECAN   BRAF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    28783719 26989027 22180495 26687137 19603024 27729313 25714871 19603018


    Sources:
    JAX-CKB CIViC

  • IRINOTECAN   KRAS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Selumetinib
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    20619739 24042735 16707468 21325073 23209031 25714871 24798549 26341920 25567130 25322874 21575616


    Sources:
    JAX-CKB CIViC

  • IRINOTECAN   SLC19A1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   CES1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   BRCA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Veliparib
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive

    PMIDs:
    26842236


    Sources:
    JAX-CKB

  • IRINOTECAN   MTHFR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16456808


    Sources:
    NCI

  • IRINOTECAN   VEGFA

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25955730 20125120


    Sources:
    PharmGKB

  • IRINOTECAN   TYMSOS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   MAPK10

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16799812


    Sources:
    NCI

  • IRINOTECAN   ABCC4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23478653


    Sources:
    PharmGKB

  • IRINOTECAN   ABCC2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18981587 18221820


    Sources:
    PharmGKB

  • IRINOTECAN   TGFB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27160286


    Sources:
    PharmGKB

  • IRINOTECAN   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24018773 18221820


    Sources:
    PharmGKB

  • IRINOTECAN   PIN1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • IRINOTECAN   ATM

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive
    combination therapy Irinotecan + Veliparib

    PMIDs:
    27638859


    Sources:
    JAX-CKB

  • IRINOTECAN   PIK3CA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    24042735 16707468 21325073 25714871


    Sources:
    JAX-CKB

  • IRINOTECAN   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871


    Sources:
    JAX-CKB

  • IRINOTECAN   NR1I2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27561454 27116457


    Sources:
    PharmGKB

  • IRINOTECAN   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • IRINOTECAN   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Veliparib
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive

    PMIDs:
    26842236


    Sources:
    JAX-CKB

  • IRINOTECAN   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Nimotuzumab
    Indication/Tumor Type stomach cancer
    Response Type predicted – sensitive

    PMIDs:
    25185971 23209031


    Sources:
    JAX-CKB

  • IRINOTECAN   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25601188


    Sources:
    CIViC

  • IRINOTECAN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27845419


    Sources:
    PharmGKB

  • IRINOTECAN   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    25567130


    Sources:
    JAX-CKB

  • IRINOTECAN   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TdgClinicalTrial: IRINOTECAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: IRINOTECAN

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1996

    Publications:

  • NCI: IRINOTECAN

    • Version: 14-September-2017

    Alternate Names:
    C1381 NCI drug code

    Drug Info:

    Publications:
    Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
    Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.
    Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer

  • DTC: IRINOTECAN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL481 ChEMBL Drug ID

    Drug Info:

    Publications:
    Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
    Chaniyara R et al., 2013, Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition., J Med Chem
    de Oliveira Figueiredo P et al., 2014, Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids., Bioorg Med Chem Lett

  • JAX-CKB: Irinotecan

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
    Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature

  • PharmGKB: irinotecan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Takahashi H et al., 2014, Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect., PLoS One
    Fujita K et al., 2008, Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)., Biol Pharm Bull
    Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer

  • CIViC: IRINOTECAN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Loupakis et al., 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer., Br. J. Cancer
    Silkin SV et al., 2016, Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan., J Gastrointest Cancer

  • TTD: Irinotecan

    • Version: 2020.06.01

    Alternate Names:
    D07HOB TTD Drug ID

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: IRINOTECAN

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL481

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: IRINOTECAN

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: IRINOTECAN

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Irinotecan

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21